National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Letermovir (Prevymis®)

Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).

NCPE Assessment Process Complete
Rapid review commissioned 12/03/2018
Rapid review completed 10/05/2018
Rapid Review outcome A Full pharmacoeconomic assessment is recommended
HTA commissioned by the HSE 29/05/2018
Pre-submission consultation with Applicant 09/07/2018
Submission received from Applicant 02/04/2019
Preliminary review sent to Applicant 29/08/2019
NCPE assessment re-commenced 27/09/2019
Preliminary review # 2 sent to Applicant 25/11/2019
NCPE assessment re-commenced 05/12/2019
Factual accuracy check sent to Applicant 24/04/2020
NCPE assessment re-commenced 01/05/2020
NCPE assessment complete 19/05/2020
NCPE assessment outcome The NCPE recommends that letermovir be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations March 2021.